
Officials with the FDA have granted accelerated approval to pembrolizumab (Keytruda, Merck) for 2 new indications, including the treatment of refractory primary mediastinal large B-cell lymphoma (PMBCL), and recurrent metastatic cervical cancer in previously treated patients whose tumors express PD-L1.































